Aduro Biotech Inc. (NASDAQ:ADRO)‘s stock had its “buy” rating reaffirmed by research analysts at Roth Capital in a research report issued to clients and investors on Friday. They presently have a $20.00 price target on the stock. Roth Capital’s price objective would indicate a potential upside of 43.37% from the company’s previous close.
A number of other research analysts have also recently issued reports on the company. FBR & Co reiterated a “buy” rating on shares of Aduro Biotech in a research note on Tuesday. Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the stock a “buy” rating in a research note on Monday, November 21st. Finally, Leerink Swann set a $14.00 price objective on Aduro Biotech and gave the stock a “buy” rating in a research note on Monday, October 24th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $19.60.
Aduro Biotech (NASDAQ:ADRO) opened at 13.95 on Friday. The stock’s market cap is $937.19 million. Aduro Biotech has a 12 month low of $7.26 and a 12 month high of $34.95. The stock’s 50 day moving average price is $12.58 and its 200-day moving average price is $12.94.
Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.45) by $0.09. The company had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $3.99 million. Aduro Biotech had a negative net margin of 72.04% and a negative return on equity of 23.45%. The firm’s quarterly revenue was down 79.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.01 EPS. Analysts anticipate that Aduro Biotech will post ($1.34) EPS for the current fiscal year.
In other news, insider Jennifer Lew sold 6,360 shares of the firm’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $14.95, for a total transaction of $95,082.00. Following the sale, the insider now directly owns 48,955 shares in the company, valued at approximately $731,877.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen T. Isaacs sold 27,273 shares of the firm’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $12.67, for a total value of $345,548.91. Following the sale, the chief executive officer now owns 129,473 shares in the company, valued at $1,640,422.91. The disclosure for this sale can be found here. Company insiders own 6.50% of the company’s stock.
Large investors have recently bought and sold shares of the company. Jennison Associates boosted its stake in Aduro Biotech by 4.2% in the third quarter. Jennison Associates now owns 781,265 shares of the company’s stock valued at $15,097,000 after buying an additional 31,366 shares during the last quarter. Janus Capital Management purchased a new stake in Aduro Biotech during the third quarter valued at about $32,842,000. Marquette Asset Management Inc. purchased a new stake in Aduro Biotech during the fourth quarter valued at about $9,849,000. California State Teachers Retirement System boosted its stake in Aduro Biotech by 2.3% in the fourth quarter. California State Teachers Retirement System now owns 15,503 shares of the company’s stock valued at $436,000 after buying an additional 355 shares during the last quarter. Finally, DUPONT CAPITAL MANAGEMENT Corp purchased a new stake in Aduro Biotech during the fourth quarter valued at about $321,000. Institutional investors own 28.50% of the company’s stock.
About Aduro Biotech